X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs VENUS REMEDIES - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE VENUS REMEDIES STRIDES PHARMA SCIENCE/
VENUS REMEDIES
 
P/E (TTM) x 51.7 -3.8 - View Chart
P/BV x 1.1 0.1 788.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   VENUS REMEDIES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
VENUS REMEDIES
Mar-18
STRIDES PHARMA SCIENCE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,147126 911.0%   
Low Rs64261 1,050.7%   
Sales per share (Unadj.) Rs317.2301.8 105.1%  
Earnings per share (Unadj.) Rs7.8-24.9 -31.5%  
Cash flow per share (Unadj.) Rs25.12.5 984.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.3293.3 93.5%  
Shares outstanding (eoy) m89.5012.34 725.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.3 910.1%   
Avg P/E ratio x114.0-3.8 -3,033.0%  
P/CF ratio (eoy) x35.736.7 97.2%  
Price / Book Value ratio x3.30.3 1,023.1%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0581,154 6,938.7%   
No. of employees `0002.50.9 271.0%   
Total wages/salary Rs m4,341393 1,104.2%   
Avg. sales/employee Rs Th11,325.84,026.1 281.3%   
Avg. wages/employee Rs Th1,731.4425.0 407.4%   
Avg. net profit/employee Rs Th280.1-331.8 -84.4%   
INCOME DATA
Net Sales Rs m28,3943,724 762.4%  
Other income Rs m94123 4,180.4%   
Total revenues Rs m29,3343,747 783.0%   
Gross profit Rs m3,965395 1,004.4%  
Depreciation Rs m1,540338 455.3%   
Interest Rs m1,962354 553.9%   
Profit before tax Rs m1,403-275 -509.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m9732 307.9%   
Profit after tax Rs m702-307 -228.8%  
Gross profit margin %14.010.6 131.7%  
Effective tax rate %6.9-11.5 -60.4%   
Net profit margin %2.5-8.2 -30.0%  
BALANCE SHEET DATA
Current assets Rs m24,8362,638 941.6%   
Current liabilities Rs m18,9932,305 824.1%   
Net working cap to sales %20.68.9 230.1%  
Current ratio x1.31.1 114.3%  
Inventory Days Days71135 52.4%  
Debtors Days Days11346 244.8%  
Net fixed assets Rs m34,2894,871 704.0%   
Share capital Rs m895123 725.3%   
"Free" reserves Rs m23,6513,496 676.6%   
Net worth Rs m24,5463,619 678.2%   
Long term debt Rs m15,5131,374 1,128.7%   
Total assets Rs m65,4377,509 871.5%  
Interest coverage x1.70.2 769.2%   
Debt to equity ratio x0.60.4 166.4%  
Sales to assets ratio x0.40.5 87.5%   
Return on assets %4.10.6 645.0%  
Return on equity %2.9-8.5 -33.7%  
Return on capital %6.91.6 435.8%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m15,6970-   
Fx outflow Rs m735517 142.4%   
Net fx Rs m14,962-517 -2,896.7%   
CASH FLOW
From Operations Rs m1,871514 363.7%  
From Investments Rs m5,826-123 -4,732.7%  
From Financial Activity Rs m-10,157-387 2,623.8%  
Net Cashflow Rs m-2,6154 -62,259.3%  

Share Holding

Indian Promoters % 27.7 32.9 84.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.2 21,000.0%  
FIIs % 8.6 0.6 1,482.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 66.4 39.0%  
Shareholders   56,241 20,121 279.5%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 14, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS